ESMO 2025 | CLEAR: final analysis of lenvatinib & pembrolizumab in aRCC with bone metastases
Camillo Porta, MD, A. Moro University of Bari, Bari, Italy, discusses the final analysis of the Phase III CLEAR study (NCT02811861), which evaluated lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (aRCC), including those with baseline bone metastases. Lenvatinib and pembrolizumab demonstrated superior progression-free survival, overall survival, and objective response rates compared with sunitinib, even in patients with adverse baseline prognostic factors. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We performed a sub-analysis of the CLEAR study that was aimed at comparing the combination of Pembrolizumab plus Lenvatinib versus Sunitinib in metastatic kidney cancer patients, and we focused for this poster on patients with bone metastasis. Ultimately, we were able to demonstrate that the activity of the combination, which is already a standard treatment in metastatic kidney cancer, is guaranteed also in patients with bone metastasis, which have usually a negative prognostic impact on patients...
We performed a sub-analysis of the CLEAR study that was aimed at comparing the combination of Pembrolizumab plus Lenvatinib versus Sunitinib in metastatic kidney cancer patients, and we focused for this poster on patients with bone metastasis. Ultimately, we were able to demonstrate that the activity of the combination, which is already a standard treatment in metastatic kidney cancer, is guaranteed also in patients with bone metastasis, which have usually a negative prognostic impact on patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
